Written and maintained by CASRAI Editorial Board
Last updated
This page describes products and general use; it is not medical advice.
Who uses it: a cranial electrotherapy stimulation device (also called a CES device) is used by patients under a prescriber’s direction. Clinic staff, buyers and students read its regulatory status and labeling to understand what the device is cleared or approved for.
What a cranial electrotherapy stimulation device is
A cranial electrotherapy stimulation device is, in FDA’s wording, “a prescription device that applies electrical current that is not intended to induce a seizure to a patient’s head to treat psychiatric conditions” (21 CFR 882.5800(a)). The regulation calls it a cranial electrotherapy stimulator; a CES device is the same product class under a shorter name.
It delivers low-level current through electrodes at the head. It is a different product class from general microcurrent therapy devices, which this site covers separately.
Parts and electrodes
A CES system is a stimulator unit that generates the current, plus patient-contact electrodes. FDA’s AccessGUDID lists electrodes of this kind as their own device components: for example, a record titled “Alpha-Stim Earclip Electrode (M)” from Electromedical Products International carries the product code JXK, “Stimulator, Cranial Electrotherapy” (checked 2026-10-31). Because the electrodes touch the patient, the regulation requires the parts that come into human contact to be shown to be biocompatible (21 CFR 882.5800(b)(1)(ii)). For the wider biocompatibility framework, see FDA guidance on biocompatibility.
FDA class depends on intended use
The same type of device sits in different FDA classes depending on the condition it is intended to treat. This is the most useful fact to check first for any CES device.
| Intended use stated for the device | FDA classification | What it means |
|---|---|---|
| Insomnia and/or anxiety | Class II (special controls) | Must meet the special controls in 21 CFR 882.5800(b)(1), including required labeling. |
| Depression | Class III (premarket approval) | Needs an approved PMA, or a declared completed PDP, before commercial distribution (21 CFR 882.5800(b)(2) and (c)). |
Source: 21 CFR 882.5800, final rule 84 FR 70013 (December 20, 2019), checked 2026-10-31. FDA’s own product-code listings for individual CES devices differ, so the device’s own clearance or approval record is the authority for its status. For the difference between the two pathways, see 510(k) vs PMA and FDA 510(k) premarket notification.
What the 2019 reclassification changed for older devices
Class II devices marketed before the reclassification must have an amendment to their previously cleared 510(k) showing compliance with the special controls (882.5800(b)(1)(vii)). For depression-type uses, a PMA or PDP notice of completion was due on or before March 19, 2020 for qualifying pre-amendment and substantially equivalent devices, and any other device with that use needs an approved PMA or declared completed PDP in effect before distribution (882.5800(c)).
What the labeling must include
For Class II devices, 21 CFR 882.5800(b)(1)(vi) lists what the labeling must contain. This works as a checklist when staff review a device’s instructions for use.
| Required labeling element | Regulation text, summarized |
|---|---|
| Intended use | The intended use population and the intended use environment (A) |
| Monitoring warning | Patients should be monitored by their physician for signs of worsening (B) |
| Headache warning | How to mitigate the risk of headaches and what to do if one occurs (C) |
| Dizziness warning | How to mitigate the risk of dizziness and what to do if it occurs (D) |
| Clinical testing summary | Clinical outcomes, plus a summary of adverse events and complications (E) |
| Instructions for use | Electrode placement, stimulation settings and session duration and frequency are stated in the labeling, based on the device’s clinical study results (F) |
| Technical parameters | Waveform, output mode, pulse duration, frequency, train delivery, maximum charge and energy (G) |
| Reprocessing | Validated methods for reprocessing any reusable components between uses (H) |
The special controls also require clinical testing data for insomnia/anxiety use, electrical safety and electromagnetic compatibility testing for the intended use environment, software verification, validation and hazard analysis, and full characterization of the technical parameters (882.5800(b)(1)(i), (iii), (iv), (v)).
Safe use and handling basics
The regulation sets the safety content a labeled device must carry: physician monitoring for worsening, and written guidance on headaches and dizziness. Use, electrode placement and session settings come from the manufacturer’s instructions for use and the prescriber, not from this page. Reusable components need the manufacturer’s validated reprocessing method between uses.
Common mistakes
- Treating every CES device as one class. Class II versus Class III turns on the intended use, so check the stated indication.
- Treating it as an over-the-counter product. The regulation defines the device as a prescription device.
- Assuming older devices are exempt. Devices marketed before the 2019 reclassification must also demonstrate compliance with the special controls.
- Skipping the labeling review. A Class II device whose instructions lack the items above does not match the regulation’s labeling requirement.
FAQ
What is a CES device?
CES stands for cranial electrotherapy stimulation. A CES device is a prescription device that applies non-seizure-inducing electrical current to a patient’s head to treat psychiatric conditions (21 CFR 882.5800(a)).
Is a CES device a Class II or Class III device?
Class II (special controls) when intended to treat insomnia and/or anxiety, and Class III (premarket approval) when intended to treat depression (21 CFR 882.5800(b)).
Does a CES device need a prescription?
The regulation identifies the device as a prescription device (21 CFR 882.5800(a)).
Sources
- 21 CFR 882.5800, Cranial electrotherapy stimulator, 84 FR 70013 (Dec. 20, 2019): law.cornell.edu/cfr/text/21/882.5800 (checked 2026-10-31).
- eCFR, 21 CFR 882.5800: ecfr.gov, section 882.5800 (checked 2026-10-31).
- NLM AccessGUDID, device record for the Alpha-Stim Earclip Electrode (M): accessgudid.nlm.nih.gov (checked 2026-10-31).
